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Abstract
Background: Adenosine cardiovascular magnetic resonance (CMR) can accurately quantify myocardial perfusion
reserve. While regadenoson is increasingly employed due to ease of use, imaging protocols have not been
standardized. We sought to determine the optimal regadenoson CMR protocol for quantifying myocardial perfusion
reserve index (MPRi) – more specifically, whether regadenoson stress imaging should be performed before or after
rest imaging.
Methods: Twenty healthy subjects underwent CMR perfusion imaging during resting conditions, during
regadenoson-induced hyperemia (0.4 mg), and after 15 min of recovery. In 10/20 subjects, recovery was facilitated
with aminophylline (125 mg). Myocardial time-intensity curves were used to obtain left ventricular cavity-normalized
myocardial up-slopes. MPRi was calculated in two different ways: as the up-slope ratio of stress to rest (MPRi-rest),
and the up-slope ratio of stress to recovery (MPRi-recov).
Results: In all 20 subjects, MPRi-rest was 1.78 ± 0.60. Recovery up-slope did not return to resting levels, regardless
of aminophylline use. Among patients not receiving aminophylline, MPRi-recov was 36± 16% lower than MPRi-rest
(1.13 ± 0.38 vs. 1.82±0.73, P = 0.001). In the 10 patients whose recovery was facilitated with aminophylline,
MPRi-recov was 20± 24% lower than MPRi-rest (1.40 ± 0.35 vs. 1.73± 0.43, P = 0.04), indicating incomplete reversal.
In 3 subjects not receiving aminophylline and 4 subjects receiving aminophylline, up-slope at recovery was greater
than at stress, suggesting delayed maximal hyperemia.
Conclusions: MPRi measurements from regadenoson CMR are underestimated if recovery perfusion is used as a
substitute for resting perfusion, even when recovery is facilitated with aminophylline. True resting images should be
used to allow accurate MPRi quantification. The delayed maximal hyperemia observed in some subjects deserves
further study.
Trial registration: ClinicalTrials.gov NCT00871260
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In recent years, vasodilator stress cardiovascular magnetic
resonance (CMR) perfusion imaging has been shown to
be a sensitive and specific means of diagnosing coronary
artery disease [1-9]. CMR also offers a wealth of data
regarding myocardial structure and function, without
exposing patients to ionizing radiation, and aids in risk
stratification for future adverse cardiovascular events
[10-12]. Because of these advantages, vasodilator CMR is a
rapidly burgeoning methodology.
Most commonly, vasodilator stress CMR is performed
with adenosine. This drug requires a continuous infusion,
such that separate IV lines are required for vasodilator and
contrast agent. Due to activation of A1,A 2B and A3 recep-
tors, adenosine has a variety of undesirable side effects,
which include atrioventricular (AV) block, hypotension,
and bronchospasm [13]. These occurrences can interrupt
workflow and, in rare circumstances, compromise patient
safety [14]. Regadenoson, a selective A2A receptor agonist,
is an appealing alternative for stress CMR because it is
administered as a single, standard-dose bolus (such that
only one IV line is required) and has a more favorable
side-effect profile [15,16]. We have demonstrated the feasi-
bility and safety of regadenoson CMR and have shown that
perfusion defects on stress CMR images predict future
need for revascularization [17]. One advantage of stress
CMR is the ability to quantify myocardial perfusion
reserve (MPR), which is less dependent upon interpreter
expertise and improves the accuracy of the detection of
multivessel coronary artery disease [18]. Others have
shown that MPR obtained by vasodilator stress CMR is
similar, regardless of whether hyperemia is induced with
adenosine or regadenoson [19].
Because the half-life of adenosine is 2–10 seconds [16],
and thus the hyperemic effects of the drug are expected to
be completely resolved after 10–15 minutes, stress CMR
imaging with adenosine is often performed before rest im-
aging [10,20,21]. This stress followed by rest approach
eliminates the possibility that stress images could be
contaminated by delayed enhancement from previously
administered gadolinium-based contrast, potentially mask-
ing the presence of perfusion defects.
Clinicians often perceive regadenoson as a short-acting
agent because its side effects are short-lived, but the drug
has a terminal half-life of approximately 2 hours [22].
After administration, it redistributes rapidly throughout
the body, followed by slower elimination. Due to regade-
noson’s longer half-life, recovery is occasionally facilitated
with aminophylline before resting images are acquired
[17,23]. However, the residual impact of regadenoson on
coronary blood flow during the clearance period is not
known.
Accordingly, the goals of this study were: (1) to deter-
mine whether a stress-recovery regadenoson CMR
protocol can reliably quantify myocardial perfusion
reserve as compared to a rest-stress protocol, (2) to
ascertain whether post-stress aminophylline administra-
tion results in a complete return of myocardial perfusion
to a pre-stress level, and (3) to establish a reference
range for MPR index (MPRi) in normal volunteers.
Methods
Study subjects
Twenty healthy volunteers (70% female, 70% Caucasian,
mean age 32± 10 yr) were prospectively recruited for
vasodilator CMR. Exclusion criteria were: history of co-
ronary artery disease, congestive heart failure, or dia-
betes mellitus; non-sinus rhythm; any contraindication
to regadenoson (including heart block, chronic obstruc-
tive pulmonary disease, or severe asthma); and any
contraindication to contrast-enhanced CMR (including
history of chronic kidney disease with glomerular filtra-
tion rate <30 mL/min, implantable pacemaker or defib-
rillator, severe claustrophobia, or adverse reaction to
gadolinium-based contrast agents). All subjects were
instructed not to consume caffeine for 12 hours prior to
the test. A 12-lead ECG was performed in each subject
prior to imaging to rule out high-degree AV nodal block.
The University of Chicago institutional review board
approved the study.
CMR image acquisition protocol
Myocardial structure and function
CMR images were acquired using a 1.5-T scanner
(Achieva, Philips, Best, Netherlands) and a 5-element
phased array cardiac coil. Retrospectively gated cine
images were obtained with a steady-state free precession
(SSFP) sequence (TR 2.9 ms, TE 1.5 ms, flip angle 60°,
and temporal resolution ~40 ms). A stack of short-axis
slices (8 mm thickness, 2 mm gap) from base to apex
was acquired. Standard 2-, 3-, and 4-chamber long-axis
views were also obtained.
Myocardial perfusion imaging
A hybrid gradient echo/echo planar imaging sequence
(voxel size ~2.57×2.5 mm, slice thickness 10 mm, flip angle
20°, repetition time 5.9 ms, echo time 2.5 ms, EPI factor 5,
delay time 80 ms, and SENSE factor 1.3) was used to
acquire short-axis slices at 3 levels of the left ventricle (LV)
during first pass of gadobenate dimeglumine (0.05 mmol/
kg at 4 mL/sec, 15 patients) or gadolinium-DTPA
(0.025 mmol/kg at 4 mL/sec, 5 patients) for 50 consecutive
heartbeats. All subjects underwent myocardial perfusion
imaging during 3 separate physiologic states, each sepa-
rated by 15 minutes: (1) resting conditions, (2) 1 minute
after regadenoson administration (Lexiscan 0.4 mg IV
bolus, Astellas Pharma), and (3) during recovery. In 10 ran-
domly selected subjects, recovery was facilitated with
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stress imaging (Figure 1). Heart rate was monitored con-
tinuously, and mean arterial blood pressure was recorded
at rest, at peak stress, and during recovery.
Late gadolinium enhancement imaging
Late gadolinium enhancement (LGE) images with slice
positions identical to the above described cines were
obtained 5–10 minutes after the third infusion of con-
trast, using a T1-weighted gradient echo pulse sequence
with a phase sensitive inversion recovery reconstruction
(TR 4.5 ms, TE 2.2 ms, TI 250-300 ms, flip angle 30°, flip
angle 5°, voxel size 2x2x10mm, SENSE factor 2). Opti-
mal inversion time was chosen based on a TI scout
(typically 250–300 ms).
Image analysis
Images were analyzed with a commercial software pack-
age (Philips View Forum, Best, Netherlands). Short-axis
cine slices were used to measure ventricular volumes
and ejection fractions (LVEF) using the Simpson method
of disks. For semi-quantitative perfusion analysis, epicar-
dial and endocardial borders of the mid-LV slice were
manually traced for each frame, myocardial segmenta-
tion was applied, and time-signal intensity curves were
generated for each myocardial segment and the LV ca-
vity. The maximum myocardial up-slopes were normal-
ized to the LV cavity up-slope and averaged for all
myocardial segments (Figure 2). MPRi was calculated as
both (1) the up-slope ratio of stress to rest (MPRi-rest)
and (2) the up-slope ratio of stress to recovery (MPRi-
recov). Cine, perfusion, and LGE images were visually
assessed by a CMR expert (ARP).
Statistical analysis
Continuous variables were analyzed using student’s
t-tests (paired for intragroup comparisons, unpaired for
intergroup comparisons; equal variances were not
assumed). Categorical variables were analyzed with
Fisher’s exact test.
Results
Table 1 shows the basic characteristics and hemodynamic
data of the two groups of subjects: 10 subjects who
received aminophylline and the remaining 10 subjects. All
subjects had normal LVEFs (>50%) and LV end-diastolic
volume indices, with no regional wall motion abnorma-
lities, late gadolinium enhancement, or perfusion defects.
In all subjects, regadenoson significantly increased the
heart rate above baseline (mean increase 52±13 beats per
min, P<0.001). Patients receiving aminophylline post-
stress had a significantly larger fall in heart rate from stress
to recovery (mean decrease 48±11 vs. 35±12 beats per
min, P=0.03; Table 1). Common side effects of regadeno-
son included dyspnea or difficulty with breath holds
(45%), palpitations (35%), chest pressure or heaviness
(35%), and flushing (25%). Two subjects reported dysgeu-
sia immediately following aminophylline administration.
Side effects did not cause any significant delays in scan-
ning, and no adverse events occurred.
In all 20 subjects, myocardial perfusion (as estimated
by normalized up-slope) increased from rest to stress:
mean rest up-slope was 8.26 ±2.40, and stress up-slope
was 14.50 ± 6.21 (P <0.001). Regardless of aminophylline
administration, recovery up-slope was higher than rest
up-slope and not significantly different from stress up-
slope (Table 2). Among patients who did not receive
aminophylline, myocardial perfusion up-slope was con-
sistently greater at recovery than at rest (mean increase
68± 54%, P<0.01; figure 3). In the aminophylline-
facilitated recovery group, all but 2 subjects had greater
perfusion up-slopes at recovery than at rest (mean in-
crease 34±37%, P =0.02).
Mean MPRi-rest for all 20 subjects was 1.78 ±0.60.
Regardless of aminophylline administration, MPRi-recov
was lower than MPRi-rest, suggesting incomplete reco-
very from hyperemia. In the non-aminophylline group,
mean MPRi-recov was 36 ±16% lower than MPRi-rest
(1.13 ±0.38 vs. 1.82 ±0.73, P =0.001). In the aminophyl-
line group, mean MPRi-recov was 20 ±24% lower than
MPRi-rest (1.40± 0.35 vs. 1.73 ±0.43, P= 0.04; Table 3).
Although the absolute difference between MPRi-rest and
MPRi-recov tended to be smaller in the aminophylline
group as compared to the non-aminophylline group, this
Figure 1 CMR protocol. Perfusion imaging sequences are separated by 15-min intervals as shown.
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intergroup comparison).
Three subjects in the non-aminophylline group and 4
in the aminophylline group had increased myocardial
perfusion indices at recovery as compared to stress
(Figure 3). These 7 patients exhibited no significant dif-
ferences in age, body surface area, or gender distribution
as compared to all other subjects. Baseline diastolic
blood pressure was slightly higher in this group (68± 12
vs. 55±11 mmHg, P =0.04). Although subjects in this
group tended to have greater heart rate increases at
stress, this difference was not statistically significant (56
vs. 50 bpm, P= 0.33). Subjects with more hyperemia at
recovery than at stress, by definition, all had MPRi-
recov <1, and MPRi-recov was 43± 11% lower than
MPRi-rest (0.80 ±0.16 vs. 1.39 ±0.10, P<0.001). As
compared to subjects who were maximally hyperemic at
stress, those who were maximally hyperemic at recovery
had lower MPRi-rest (1.39 ±0.10 vs. 1.99 ±0.68, P =
0.008), lower MPRi-recov (0.80 ±0.16 vs. 1.52± 0.41, P <
Figure 2 A. Example of myocardial tracing and segmentation in a short-axis slice. Endocardial border is shown in green and epicardial
border in yellow. The LV myocardium was segmented into 4 sectors (anterior, lateral, inferior, septal). B. Blood pool and segmental myocardial
time-intensity curves. Maximum up-slopes (black lines) were determined for the blood pool and for each myocardial segment; the mean
myocardial up-slope was then normalized to the blood pool up-slope.
Table 1 Patient demographics and hemodynamic responses to regadenoson
Aminophylline No aminophylline P
value (n= 10) (n= 10)
Age (yr) 32 (7) 32 (13) 0.90
% female 70 50 0.65
% Caucasian 70 50 0.65
LVEF (%) 61 (5) 61 (5) 0.97
LVEDV index (mL/m
2) 85 (9) 84 (14) 0.89
Baseline HR (BPM) 68 (9) 65 (14) 0.67
HR change, baseline to stress (BPM) +55 (11) +48 (13) 0.22
HR change, stress to recovery (BPM) −48 (11) −35 (12) 0.03
HR change, rest to recovery (BPM) +7 (9) +13 (12) 0.24
Baseline MAP (mmHg) 77 (11) 78 (12) 0.75
Change in MAP, baseline to stress (mmHg) +3 (10) +4 (7) 0.81
SD, standard deviation; LVEF, left ventricular ejection fraction; LVEDV, left ventricular end-diastolic volume; HR, heart rate; BPM, beats per minute; MAP, mean
arterial pressure. Data in parentheses are standard deviations.
Bhave et al. Journal of Cardiovascular Magnetic Resonance 2012, 14:89 Page 4 of 8
http://www.jcmr-online.com/content/14/1/890.001), and higher recovery-to-rest ratios (1.84± 0.53 vs.
1.33 ±0.35, P= 0.05). The recovery-to-rest ratios in the
delayed hyperemia group were similar to MPRi-rest in
the remaining patients (1.84 ±0.53 vs. 1.99 ±0.68,
P =0.58).
Discussion
Vasodilator stress CMR is being increasingly incorporated
into clinical practice for the evaluation of coronary artery
disease because of its superior diagnostic performance
when compared to single photon emission computed
Table 2 Regadenoson CMR perfusion up-slopes at rest, stress, and recovery, with and without aminophylline
Rest up-slope
(SD)
Stress up-slope
(SD)
Recovery up-slope
(SD)
P value, recovery vs.
rest
P value, recovery vs.
stress
No
Aminophylline
8.79 (2.98) 15.99 (8.38) 14.08 (4.03) <0.001 0.64
Aminophylline 7.73 (1.64) 13.01 (2.53) 10.19 (2.98) 0.02 0.08
Data in parentheses are standard deviations.
Figure 3 Comparison of perfusion up-slopes at stress and recovery, normalized for rest up-slope, on a per-patient basis. Four subjects
in the aminophylline group and 3 subjects in the no-aminophylline group had greater perfusion at recovery than at stress.
* P<0.001;
† P= 0.08;
**P =0.02;
‡ P= 0.01;
ʃ P=0.38.
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improved side-effect profile compared to adenosine,
regadenoson is being used more frequently to induce
hyperemia during vasodilator stress CMR. However, opti-
mal protocols for regadenoson CMR have not yet been
established. In this study, we found that: (1) regadenoson-
induced hyperemia persists to a degree, even after 15 min-
utes of recovery; (2) recovery facilitated with aminophylline
only partially reverses the residual regadenoson-induced
hyperemia; and (3) some individuals may have delayed
maximal hyperemia following the administration of rega-
denoson. Therefore, when regadenoson myocardial perfu-
sion imaging is performed prior to recovery perfusion
imaging, the calculated myocardial perfusion reserve may
significantly underestimate the actual myocardial perfusion
reserve, irrespective of whether aminophylline is used to
reverse hyperemia.
One particular strength of stress CMR is its ability to as-
sess myocardial perfusion, quantitatively or semi-quantita-
tively, as an adjunct to visual analysis. Assessment of
myocardial perfusion reserve has been shown to reduce
inter-reader variability and to quantify more accurately the
severity of localized ischemia due to epicardial coronary
stenosis [24], particularly when ischemia is present in mul-
tiple vascular territories [18]. Myocardial perfusion reserve
by CMR can also reveal diffuse ischemia attributable to
microvascular dysfunction [25], and is a potentially useful
tool for identifying subclinical disease in patients with car-
diovascular risk factors [26,27].
We have established, albeit in a relatively small group
of normal subjects, a reference range for MPRi-rest with
regadenoson, as determined semi-quantitatively using
the time-intensity up-slope technique with a hybrid
gradient echo/echo planar imaging sequence. Perfusion
analysis by this method is rapid enough for routine clin-
ical use and does not require cumbersome dual-bolus
imaging, which may be desirable when MPR is deter-
mined quantitatively by deconvolution methods [28].
DiBella and colleagues have previously compared perfu-
sion reserve with regadenoson to that with adenosine
and found good agreement, using an ultra-fast gradient
echo sequence (Turbo FLASH, Siemens) and deconvolu-
tion. However, their study included patients with CAD
and cardiovascular risk factors, so their findings cannot
be used as reference values [19]. Based on our mean
MPRi-rest 1.78 ±0.60, we calculate that a 58-patient
sample size would be needed to detect a 25% difference
in perfusion reserve between normals and abnormals
(80% power, α =0.05). Accordingly, in future drug trials
aimed at treatment of microvascular dysfunction, rega-
denoson stress CMR could allow detection of significant
differences in perfusion reserve in relatively small
cohorts. Our reported normal ranges may also be useful
for the development of appropriate semi-quantitative
regadenoson stress CMR cut-off values for detecting sig-
nificant coronary disease and microvascular dysfunction.
Aminophylline is a dissociable complex of theophylline, a
methylxanthine adenosine receptor antagonist, and ethylene-
diamine, which improves solubility. In one small cardiac
catheterization study, aminophylline appeared to reverse
regadenoson-induced hyperemia to some degree. In subjects
receiving aminophylline, coronary blood flow fell below 2-
fold of baseline within <1 min, whereas subjects not receiv-
ing aminophylline remained above 2-fold of baseline for an
additional 7 min. Notably, at the 10-minute mark, neither
group of subjects returned to baseline perfusion [23].
In our subjects, we suspect that persistent hyperemia oc-
curred in the post-regadenoson recovery phase due to re-
sidual vasodilatory effects of the drug, given its relatively
long terminal half-life [23]. Although regadenoson has a
relatively weak affinity for the A2A receptor [29], such that
its peak vasodilatory effect is brief, drug that is distributed
throughout the tissues may return to the blood compart-
ment during recovery and cause a low level of coronary
vasodilation. While aminophylline seems to help alleviate
the side effects of regadenoson, and is therefore often used
as an antidote, its ability to reverse the coronary vasodila-
tory effects of regadenoson has not been fully described. In
our subjects, aminophylline did not eliminate the vasodila-
tory effects of regadenoson – that is, some degree of
hyperemia persisted at recovery in most subjects who
received aminophylline. Our results are consistent with
those of the previously mentioned catheterization study, in
which intracoronary blood flow was measured invasively
after regadenoson administration; although the average
peak blood flow velocity was reduced by aminophylline, it
did not return to baseline by the 10-minute mark [23]. A
potential explanation for these observations is that theo-
phylline has a low affinity for the A2A receptor [30], so it
may dissociate relatively rapidly, allowing some of the re-
sidual regadenoson to rebind post-stress. Interestingly, our
aminophylline group had a significantly greater decline in
heart rate from stress to recovery, suggesting that amino-
phylline is somewhat active at the A2A receptor at 15-
Table 3 Comparison of aminophylline and no-aminophylline groups with respect to perfusion reserve
MPRi-rest, mean (SD) MPRi-recov, mean (SD) % difference (SD) P value
No Aminophylline 1.83 (0.73) 1.13 (0.38) 36 0.001
Aminophylline 1.73 (0.43) 1.40 (0.35) 20 0.04
MPRi-rest, myocardial perfusion reserve index comparing stress to rest; MPRi-recov, myocardial perfusion reserve index comparing stress to recovery. Data in
parentheses are standard deviations.
Bhave et al. Journal of Cardiovascular Magnetic Resonance 2012, 14:89 Page 6 of 8
http://www.jcmr-online.com/content/14/1/89minute follow up. Regardless, our results suggest that the
order of the study protocol is critically important if perfu-
sion reserve is to be determined by regadenoson CMR or,
similarly, by any other myocardial perfusion imaging
modality.
Although the rest-stress protocol must be used to quan-
tify perfusion reserve accurately, it is unknown if this
protocol would lower the sensitivity of regadenoson CMR
for detecting ischemic perfusion defects. Administering a
lower contrast dose at rest, in a manner similar to rest-
stress SPECT imaging, or allowing a prolonged delay be-
tween rest and stress imaging, might help mitigate this
problem. An alternative strategy would consist of a 2-day
protocol with stress imaging performed on the first day
and rest imaging performed on a subsequent day. The rest
portion could be eliminated if obvious perfusion defects
were present on the initial stress images. Of course, such
an approach would be costly and time-consuming and
would require clinical validation to justify widespread use.
Perhaps our most noteworthy finding is that several
patients demonstrated more hyperemia at recovery than
at stress. In these subjects, recovery-to-rest ratios (MPRi-
recov) were similar to stress-to-rest ratios (MPRi-rest) in
the remaining subjects, suggesting that some individuals
have a delayed maximal hyperemic response to regadeno-
son. Aminophylline appears to have little impact on this
effect. Although all these subjects had an increase in
perfusion from rest to stress, as would be expected, mean
MPRi-rest and MPRi-recov were significantly lower than
in subjects with rapid hyperemia. Interestingly, the pro-
portions of delayed-hyperemia patients in the aminophyl-
line and non-aminophylline groups were similar, leading
us to believe that this phenomenon is unlikely to have
biased our overall results. Although patients with delayed
hyperemia tended to have slightly higher diastolic blood
pressures, no values were pathologically elevated, so this is
unlikely to be a clinically useful metric. Further studies will
be needed to identify potential predictors of and explana-
tions for the delayed-hyperemic response.
The persistence of hyperemia beyond the immediate
post-stress period may raise the question of whether
patients with flow-limiting coronary stenoses can safely re-
ceive regadenoson without prolonged post-procedural
monitoring – i.e., whether such patients might still be
“ischemic” when discharged from the CMR center
immediately after scan completion. However, it is important
to note that regadenoson, like adenosine, does not typically
cause true ischemia, but rather a relative lack of hyperemia
in segments subtended by diseased vessels. Although it is
possible that regadenoson causes a prolonged discrepancy
in myocardial blood flow between territories supplied by
healthy and diseased arteries, it is unlikely that this results
in adverse clinical effects, based on the drug’s excellent
safety record in the SPECT literature [16].
Limitations
This study was conducted in a small number of healthy
volunteers. However, this number was sufficient to
answer the questions we posed with confidence, as
confirmed by statistical analysis. Based on common
practice with adenosine CMR, we performed recovery
imaging 15 minutes post-stress. It is possible that post-
regadenoson recovery imaging either earlier (i.e., 2–
3 min after aminophylline administration) or later (20–
30 min after stress) would have demonstrated a lesser
degree of residual hyperemia. As all of our subjects had
normal perfusion, we could not assess whether a rest-
stress protocol, as opposed to a stress-recovery protocol,
would mask the presence of ischemia due to contrast
contamination of stress images. Five individuals who
received a very low dose of contrast (0.025 mmol/kg)
were included in the analysis; however, their MPRi-rest
was not significantly different from the other subjects.
Finally, it is unknown whether a relatively modest
(approximately 20%) underestimation of perfusion re-
serve, as seen with MPRi-recov in patients receiving
aminophylline, would have clinical significance. Future
studies are needed to answer this question.
Conclusions
We have demonstrated that a regadenoson CMR stress-
recovery protocol underestimates perfusion reserve com-
pared to a rest-stress protocol. Therefore, for reliable quanti-
fication of myocardial perfusion reserve, the latter approach
is preferable. Further research will be needed to determine
whether a rest-stress protocol would lower the sensitivity of
regadenoson CMR for detecting ischemic perfusion defects,
and to establish the length of time between rest and stress
imaging that would be necessary to eliminate this issue.
We additionally showed that some subjects have a
delayed hyperemic response during the supposed recovery
phase; future studies are needed to elucidate the clinical
relevance and underlying explanation for this finding.
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